Little or no HER2 expression was observed on the CD14+ and CD56+ PBMCs of the healthy volunteers and HER2− breast cancer patient; similarly, little or no HER2 expression was observed on the tumor-infiltrated CD14+ and CD56+ PBMCs of the HER2− breast cancer patient. This evidence concerns the gene NCAM1 and breast cancer.